

U.S. Serial No. 08/07/2003

RECEIVED
CENTRAL FAX CENTER

DEC 04 2006

RemarksStatus of the Claims following the Office action mailed 08/08/2006

Claims 17-32 are pending.

Claims 17-32 are rejected.

Amendments to the Specification

Applicants have amended the cross-reference to related applications in order to correct informalities.

Applicants have amended the brief description of the drawings to individually describe each of the individual drawings 2A-J, 3A-I, 4A-K, and 6A-C, and to remove references to colors. Applicants note that color drawings were provided in the parent application only. In addition, Applicants have amended the descriptions of Figs. 2A-J, 3A-I, and 4 to refer to the example in which these figures are described.

Applicants have amended example 3 to remove references to colors, in accordance with the amendments to the brief description of the drawings.

The amendments to the specification do not introduce new matter. Applicants request entry of the amendments to the specification into the record.

Amendments to the Claims

Applicants have amended claim 1 to clarify the relationship between the claim elements and to specify how the method steps provide a measure of dendritic cell function.

Applicants have amended claim 30 to specify that the dendritic cell subsetting antibody is an additional antibody added during step (b) of claim 1. Claim 30 is drawn to a preferred embodiment described at page 15, lines 14-19, of the specification.

The amendments to the claims do not introduce new matter. Applicants request entry of the amendments to the claims into the record.